Drugs / IMSB301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07364513 | Jan → Jul 2026 overdue | type 1 interferonopathy | ImmuneSensor Therapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-20 | ImmuneSensor Therapeutics Inc. | Regulatory ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS) immunesensor.com ↗ |
| 2024-08-19 | ImmuneSensor Therapeutics Inc. | Regulatory ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301 immunesensor.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-12 | ImmuneSensor Therapeutics Inc. | ImmuneSensor Therapeutics Doses First Patient with Aicardi Goutières Syndrome (AGS) in Phase 1b Clinical Study of cGAS inhibitor, IMSB301 immunesensor.com ↗ |
| 2024-11-20 | ImmuneSensor Therapeutics Inc. | ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS) immunesensor.com ↗ |
| 2024-10-08 | ImmuneSensor Therapeutics Inc. | ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301 immunesensor.com ↗ |
| 2024-08-19 | ImmuneSensor Therapeutics Inc. | ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301 immunesensor.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMSB301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07364513 ↗ |